Oruka Therapeutics, Inc. (ORKA) intrinsic value & 10-year financials
Oruka Therapeutics, Inc. (ORKA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $71.93
- Market cap
- $1.0B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 440.7%
- Free cash flow (FY2025)
- -$88.4M
ORKA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$105.4M | — | -$88.4M | — | -28.2% |
| FY2024 | — | — | — | — | — | — |
| FY2023 | $0 | -$5.3M | -$0.37 | -$5.0M | — | 2087.6% |
| FY2022 | $0 | -$9.9M | -$0.69 | -$10.9M | — | 873.9% |
| FY2021 | $0 | -$19.3M | -$1.39 | -$18.8M | — | 949.2% |
| FY2020 | $0 | -$9.7M | — | -$7.7M | — | 455.7% |
| FY2019 | $0 | -$5.5M | — | -$4.8M | — | -82.7% |
| FY2018 | $0 | -$7.9M | — | -$8.2M | — | -99.2% |
| FY2017 | $0 | -$18.5M | — | -$17.5M | — | -114.9% |
| FY2016 | $0 | -$16.4M | — | -$15.0M | — | -74.9% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Oruka Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Oruka Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -39.6% ROIC.
Oruka Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Oruka Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.